Date: 2013-11-21
Type of information: Fundraising
Company: Eloxx Pharmaceuticals (Israel)
Investors: Pontifax (Israel), Roche (Switzerland)
Amount:
Funding type: seed financing
Planned used:
Others: * On November 21, 2013, Eloxx Pharmaceuticals has announced the initial closing of its first round of financing with Roche and Pontifax, an Israeli VC firm leading the financing. Eloxx Pharmaceuticals is based on a technology developed by Prof. Timor Bassov from the Technion - Israel Institute of technology - enabling selective and safe ribosomal readthrough of premature termination codons for the treatment of nonsense genetic diseases.
This Pontifax portfolio company has been established in 2013 by Dr. Silvia Noiman, that serves as its Executive Chairman and Dr. Shmuel Tuvia. This biopharmaceutical company focused on discovery, development and commercialization of compounds for the treatment of genetic diseases caused by nonsense mutations including: Cystic fibrosis, Duchene Muscular Dystrophy, Usher syndrome, Ataxia-telangiectasia, Beta thalassemia, Tay-Sachs Hurler syndrome and many others. Eloxx Pharmaceuticals is building a pipeline of molecules designed for an array of nonsense genetic diseases.
Therapeutic area: Rare diseases - Genetic diseases
